My top 10-ish positions in no particular order: IGK/ISF/IDG, NRF-A/B, UVIC, GPOR, FR-J, EBIX, AEH, COPJF, CSGH, GILD, RINO, UEPS. No changes in this list since last time.
New positions: AMGN
Positions increased: DRAGF, UVIC, COPJF, IDCC, CF, HRBN, FCX, GILD, CBEH
Positions reduced: CF
Positions eliminated: None
I bought an exploratory position in AMGN, but after more research I am not sure if I will increase it. Their success in getting denosumab/Prolia approved does not cover the issue (IMHO) that they have increasing biogeneric competition and a number of patent expirations in their largest selling drugs in 2010-2015 time frame. IMHO, GILD is more attractive than AMGN.
CF is another one where I am not sure that the position is warranted at the current price. I may just hold my current stake and reevaluate when it is clearer how their Terra acquisition integration proceeds. |
